Search company, investor...

Predict your next investment

Corporation
novonordisk.com

Investments

25

Portfolio Exits

10

Partners & Customers

10

Service Providers

1

About Novo Nordisk

Novo Nordisk (CPH: NOVO-B) is a healthcare company that specializes in diabetes care. It also operates in hemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). The company was founded in 1989 and is based in Bagsvaerd, Denmark.

Headquarters Location

Novo Alle

Bagsvaerd, 2880,

Denmark

+45 4444 8888

Want to inform investors similar to Novo Nordisk about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Novo Nordisk

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Novo Nordisk in 5 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

Conference Exhibitors

5,302 items

D

Diabetes

1,903 items

M

Medical Devices

3,501 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

B

Biopharma Tech

260 items

Research containing Novo Nordisk

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Novo Nordisk in 5 CB Insights research briefs, most recently on Nov 19, 2022.

Latest Novo Nordisk News

NOVO NORDISK : Deutsche Bank gives a Buy rating

Feb 2, 2023

(marketscreener.com) Already positive, the research from Deutsche Bank and its analyst Emmanuel Papadakis still consider the stock as a Buy opportunity. The target price continues to be set at DKK 1200.https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/news/NOVO-NORDISK-Deutsche-Bank-gives-a-Buy-rating-42876901/?utm_medium=RSS&utm_content=20230202

Novo Nordisk Investments

25 Investments

Novo Nordisk has made 25 investments. Their latest investment was in Amalgam Rx as part of their Corporate Minority on December 12, 2022.

CBI Logo

Novo Nordisk Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/19/2022

Corporate Minority

Amalgam Rx

$17.37M

Yes

2

2/18/2022

Series C

Beta Bionics

$57M

No

4

3/16/2021

Series D

Glooko

$30M

Yes

14

2/10/2021

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

10/29/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/19/2022

2/18/2022

3/16/2021

2/10/2021

10/29/2019

Round

Corporate Minority

Series C

Series D

Unattributed

Series A

Company

Amalgam Rx

Beta Bionics

Glooko

Subscribe to see more

Subscribe to see more

Amount

$17.37M

$57M

$30M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

4

14

10

10

Novo Nordisk Portfolio Exits

10 Portfolio Exits

Novo Nordisk has 10 portfolio exits. Their latest portfolio exit was Disc Medicine on December 29, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/29/2022

Reverse Merger

$99M

5

7/17/2020

IPO

$99M

Public

3

8/1/2019

IPO

$99M

Public

3

5/26/2016

IPO

Subscribe to see more

$99M

Subscribe to see more

10

12/18/2014

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/29/2022

7/17/2020

8/1/2019

5/26/2016

12/18/2014

Exit

Reverse Merger

IPO

IPO

IPO

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

5

3

3

10

10

Novo Nordisk Acquisitions

12 Acquisitions

Novo Nordisk acquired 12 companies. Their latest acquisition was Forma Therapeutics on September 01, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/1/2022

Series D

$99M

$129.5M

Acq - Pending

3

12/28/2021

Series C

$99M

$123.8M

Take Private

7

7/12/2021

$99M

Acquired

1

12/8/2020

Subscribe to see more

$99M

Subscribe to see more

10

6/11/2020

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

9/1/2022

12/28/2021

7/12/2021

12/8/2020

6/11/2020

Investment Stage

Series D

Series C

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$129.5M

$123.8M

$99M

Note

Acq - Pending

Take Private

Acquired

Subscribe to see more

Subscribe to see more

Sources

3

7

1

10

10

Novo Nordisk Partners & Customers

10 Partners and customers

Novo Nordisk has 10 strategic partners and customers. Novo Nordisk recently partnered with Howwe on January 1, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

1/25/2023

Licensor

Howwe

Novo Nordisk Enters a New License Agreement for the Enterprise Execution Software Howwe®

`` We are pleased to continue the partnership with Howwe Technologies , '' said Niels Abel Bonde , General Manager & VP of Novo Nordisk .

2

12/9/2022

Partner

Rwanda

Industry news in brief

A partnership between Babyl -- a subsidiary of Babylon -- and Novo Nordisk will help contribute to the expansion of diabetes awareness and care in Rwanda through community engagement and skills building using digital technology .

1

11/21/2022

Licensor

Ireland

Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy

Prothena Corporation plc 's pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis , ATTR amyloidosis , Alzheimer 's disease , Parkinson 's disease and a number of other neurodegenerative diseases .

2

11/17/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

10/26/2022

Partner

Poland

Subscribe to see more

Subscribe to see more

10

Date

1/25/2023

12/9/2022

11/21/2022

11/17/2022

10/26/2022

Type

Licensor

Partner

Licensor

Partner

Partner

Business Partner

Howwe

Country

Rwanda

Ireland

United States

Poland

News Snippet

Novo Nordisk Enters a New License Agreement for the Enterprise Execution Software Howwe®

`` We are pleased to continue the partnership with Howwe Technologies , '' said Niels Abel Bonde , General Manager & VP of Novo Nordisk .

Industry news in brief

A partnership between Babyl -- a subsidiary of Babylon -- and Novo Nordisk will help contribute to the expansion of diabetes awareness and care in Rwanda through community engagement and skills building using digital technology .

Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy

Prothena Corporation plc 's pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis , ATTR amyloidosis , Alzheimer 's disease , Parkinson 's disease and a number of other neurodegenerative diseases .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

2

10

10

Novo Nordisk Service Providers

1 Service Provider

Novo Nordisk has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Merger

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Merger

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Novo Nordisk Team

28 Team Members

Novo Nordisk has 28 team members, including current Chief Executive Officer, President, Lars Rebien Soerensen.

Name

Work History

Title

Status

Lars Rebien Soerensen

Chief Executive Officer, President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Lars Rebien Soerensen

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer, President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.